Replies to post #330629 on Innovation Pharmaceuticals Inc (IPIX)

[KMBJN]

Whether or not brilacidin works against other viruses I believe depends on the net charge and viral protein composition of the viral membrane. Funny, just posted on this briefly before I saw your Q.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=159230057

We have talked about it elsewhere here too:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=154093083

I guess if it is just a cationic molecule like brilacidin puncturing the enveloped virus lipid bilayer, then brilacidin could work, and we should find out pretty quickly.

From https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3842434/

Quote:
Defensin perturbation of lipid bilayers is dependent upon their composition. It is favored by negatively charged phospholipids; whereas, neutral bilayers are largely inert to defensin 65; 75. The lipid content of viral envelopes is dependent upon the subcellular location and membrane microdomains from which they bud and likely varies among viral families 76. If direct membrane perturbation contributes to the antiviral effect of defensins, then differences in the lipid composition of the envelope may in part explain the differential susceptibility of viruses to defensins.


Does SARS-CoV-2 have a negatively charged lipid bilayer that is susceptible to a cationic killer like brilacidin (disrupting bacterial negatively charged outer membranes)?

So the new paper says the same as the old paper - whether brilacidin has ability to perturb the viral envelope depends on the composition of viral proteins in the envelope.

More specifically, yes I expect brilacidin to work against very many coronaviruses (MERS, SARS, and some causing the common cold like Human CoV #s 229E, NL63, OC43, and HKU1) if it works against SARS2-CoV.

Regarding the other viruses, #s 1/2/4/5/6, I doubt it, but maybe who knows until tested in a dish? Flu is an enveloped virus, as are rhinovirus and HCV, so brilacidin is more likely to work on these. Norovirus and HPV have no lipid envelope, so would be even less likely to be affected by brilacidin.

Some more about enveloped vs. non-enveloped viruses:

https://techspirited.com/difference-between-enveloped-non-enveloped-viruses

Exciting that they are planning on studying brilacidin on other viruses to find out.

Direct virucidal activity would sure be exciting, especially since brilacidin generally leaves healthy human cells alone (due to them being positively charged). See the high selectivity index. Wow!

DeGrado took what nature evolved as a natural host defense and made it even better (potentially).